Combination Antihypertensive Therapy Challenges the Dogma of Poor Drug Tolerability

Recent data challenge the long-standing perception that intensifying blood pressure–lowering therapy worsens adverse effects, a key barrier to achieving guideline-directed targets.

A large network meta-analysis of randomized trials evaluated whether antihypertensive combinations increase treatment discontinuation compared with monotherapy or placebo, addressing a critical gap between perceived and true drug tolerability.

Key Insight: Regimens containing angiotensin receptor blockers (ARBs)—particularly ARB + calcium channel blocker (CCB) combinations—demonstrated lower discontinuation rates than placebo, suggesting that some therapies may improve overall symptom burden rather than worsen it.

Notably, CCB-based regimens and certain combinations (e.g., beta-blocker + thiazide) showed higher discontinuation rates, reinforcing that drug class selection remains clinically relevant despite similar BP-lowering efficacy across agents.

A central concept is “over attribution” of adverse events, where symptoms like dizziness or fatigue are incorrectly blamed on medications, paralleling observations in statin intolerance, and contributing to undertreatment.

Importantly, guideline-directed therapy still prioritizes comorbidity-specific benefits (e.g., ACE inhibitors/ARBs in HFrEF or diabetic nephropathy) over tolerability alone, emphasizing individualized treatment.

Clinical Takeaway: Early combination therapy, especially ARB-based regimens, may improve both BP control and adherence, challenging the reflexive preference for monotherapy.

Practice Points:

• ARB + CCB combinations may optimize tolerability and adherence
• Do not overattribute nonspecific symptoms to antihypertensives
• Prioritize comorbidity-driven drug selection
• Consider upfront combination therapy in most patients

Patient Scenario:
A 58-year-old with stage 2 hypertension (160/100 mm Hg) reports fatigue on prior monotherapy and is reluctant to restart treatment.

Switching to low-dose ARB + CCB leads to improved BP (128/78 mm Hg) with no perceived side effects, illustrating how combination therapy can enhance both efficacy and tolerability.

References:

• Wang N et al. JAMA. 2026.
• McDermott MM, Persell SD. JAMA. 2026.

Prasugrel vs Ticagrelor After PCI: Is It Time to Reconsider First-Line Strategy?

Selection of P2Y12 inhibitors after PCI in acute coronary syndrome (ACS) remains a key determinant of ischemic and bleeding outcomes, with evolving data challenging long-standing preferences.

A contemporary meta-analysis of randomized trials re-examines the comparative efficacy of prasugrel, ticagrelor, and clopidogrel. While guidelines endorse prasugrel or ticagrelor over clopidogrel, the critical question is whether one potent agent is superior. Across ≈49,000 patients, prasugrel was associated with significant reductions in MACE, myocardial infarction, and stent thrombosis compared with clopidogrel, without excess major bleeding. In contrast, ticagrelor did not significantly reduce MACE versus clopidogrel, despite lowering stent thrombosis.

Head-to-head comparisons are particularly notable. Prasugrel demonstrated lower rates of MACE, MI, and stent thrombosis versus ticagrelor, aligning with prior signals from ISAR-REACT 5. Importantly, ticagrelor showed higher rates of major bleeding and intracranial hemorrhage, along with increased treatment discontinuation. Mortality differences remain neutral across agents, highlighting that benefits are driven primarily by nonfatal ischemic events.

These findings raise ongoing controversy: while ticagrelor has historically dominated practice, accumulating evidence suggests prasugrel may offer a more favorable efficacy–safety balance, particularly in invasively managed ACS patients.

Clinical Takeaway:
In appropriate patients without contraindications (e.g., prior stroke), prasugrel should be strongly considered as the preferred P2Y12 inhibitor after PCI, especially in younger, lower-bleeding-risk ACS populations.

Practice Points:
- Prasugrel reduces MACE, MI, and stent thrombosis more consistently than ticagrelor
- Ticagrelor carries higher major bleeding and intracranial hemorrhage risk
- No clear mortality difference between agents
- Consider prasugrel first-line in ACS-PCI patients without contraindications
- Individualize based on age, weight, bleeding risk, and stroke history

References:

• Maqsood MH et al. JAMA Cardiology, 2026
• ISAR-REACT 5 Trial
• ESC ACS Guidelines